<DOC>
	<DOCNO>NCT00542815</DOCNO>
	<brief_summary>This PIII multi-center , open-label , flexible dose , long-term safety study , conjunction E07 ( NCT00416520 ) , E08 ( NCT00542386 ) E09 ( NCT00451295 ) study allow exposure MCI-196 52 week</brief_summary>
	<brief_title>A Study MCI-196 Chronic Kidney Disease Stage V Subjects Dialysis With Hyperphosphatemia</brief_title>
	<detailed_description>Following completion one Phase III study ( E07 , E08 E09 ) eligible patient receive either MCI-196 52 week . The study two period . The initial period allow flexible dose period 8 week . This allow subject achieve individually optimise dos . After 8 week , subject continue flexible dose MCI-196 titration interval every 4 week instead every 2 week . Subjects previously expose MCI-196 end study Week 40 .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Hyperphosphatemia</mesh_term>
	<mesh_term>Sevelamer</mesh_term>
	<criteria>Clinically stable haemodialysis peritoneal dialysis treatment . Stable phosphate control Stabilised phosphorus diet . female subject childbearing potential must negative serum pregnancy test . Male subject must agree use appropriate contraception . Completed one MCI196 PIII study Current clinically significant medical comorbidities , may substantially compromise subject safety , expose undue risk , interfere significantly study procedure , opinion Investigator , make subject unsuitable inclusion study . Body Mass Index ( BMI ) &lt; = 16.0 kg/m2 = &gt; 40.0 kg/m2 . Current history significant gastrointestinal motility problem Positive test HIV 1 2 antibody . History substance alcohol abuse within last year . Seizure disorder . History drug allergy . Temporary catheter active sign inflammation infection . The subject participate clinical study experimental medication ( exception MCI196 PIII study ) last 30days experimental biological product within 90 day prior sign inform consent form .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Chronic Kidney Disease</keyword>
	<keyword>Dialysis</keyword>
	<keyword>Hyperphosphatemia</keyword>
</DOC>